article thumbnail

The discovery of a new and compounding cybersecurity threat to pharmacies

pharmaphorum

and Australian investors, Sam launched Kasada in 2015 to provide an innovative web traffic integrity solution to companies around the world. The post The discovery of a new and compounding cybersecurity threat to pharmacies appeared first on. He is an entrepreneur with a passion for cybersecurity. With funding from leading U.S.

article thumbnail

STAT+: Zuckerberg and Chan on track to put $50 billion toward science: ‘That’s the trajectory we’re on’

STAT

In 2015, when the self-described science nerds pledged 99 percent of their Facebook fortune to philanthropic causes over their lifetimes, they did not specify how they might spread their wealth. “The science piece is a huge, huge part of that,” Zuckerberg said when asked about his spending plans.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How cinnamon lowers blood sugar

The Checkup by Singlecare

Coumarin is a naturally occurring compound in cinnamon that can cause liver problems when consumed in high amounts or long-term, says Dr. Sapola, including liver enzyme elevation, liver toxicity, and possibly even liver cancer. This form has a higher antioxidant content and is also lower in coumarin, making it safer for long-term use.”

article thumbnail

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

European Pharmaceutical Review

According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 In 2015, Alzheimer’s Therapeutics International found there was an estimated 46.8 percent, and driven largely by collaboration of existing players, reach $6.8 percent.

article thumbnail

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

pharmaphorum

The number of AI-based drug discovery strategic alliances has increased significantly, from just 10 in 2015 to 105 in 2021, with companies like BenevolentAI, Exscientia and Insilico Medicine featuring prominently in the dealmaking.

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine.

article thumbnail

Small Pharma stock market launch funds DMT-based depression drug trial

pharmaphorum

Small Pharma is following the trend for development of psychedelic medicines, a field where research has been suppressed for years because of legal restrictions on use of these compounds in many countries. The post Small Pharma stock market launch funds DMT-based depression drug trial appeared first on.